Article 3: Tax Cuts on Cancer Drugs: A Relief, But Not a Complete Solution
Why in News: The Union Budget 2026 announced customs duty exemption on 17 cancer therapies, aiming to improve affordability of high-cost targeted and immunotherapy drugs.
Key Details
- Customs duty was removed on 17 advanced cancer medicines, including targeted therapies and immunotherapies.
- Similar exemptions were announced in previous budgets and GST Council decisions for cancer and rare disease drugs.
- Despite tax cuts, monthly treatment costs remain extremely high, often ₹2–3 lakh per patient.
- Limited insurance coverage and high out-of-pocket expenditure continue to burden households.
Rising Cancer Burden in India
- Growing Disease Load: India reports nearly 14–15 lakh new cancer cases annually, with late-stage diagnosis common due to poor screening and awareness.
- Shift Towards Advanced Therapies: Modern cancer care increasingly relies on targeted therapies, immunotherapies, and CAR-T treatments, which improve survival but are cost-intensive.
- Chronic Nature of Treatment: Many cancers now require long-term or lifelong medication, converting cancer into a chronic financial burden.
- Urban–Rural Divide: Access to advanced oncology care remains concentrated in urban tertiary hospitals, increasing travel and non-medical expenses.
Measure: Customs Duty Exemption on Cancer Drugs
- Scope of the Announcement: Customs duty was removed on 17 high-end cancer drugs, including Venetoclax, Ribociclib, CAR-T therapy agents, and immune checkpoint inhibitors.
- Policy Continuity: The move builds on earlier steps—custom duty exemption on 37 medicines (2025), interim budget reliefs, and GST removal on 36 therapies.
- Expected Price Impact: Experts estimate monthly savings of ₹20,000–₹25,000 per patient, depending on dosage and therapy duration.
- Government’s Intent: The policy aligns with the objective of making life-saving drugs accessible and reducing the cost of imports for patented medicines.
Limited Relief for Patients: Ground Reality
- High Absolute Costs Persist: Even after duty cuts, drugs like Venetoclax cost ₹75,000–₹1 lakh per month, while total monthly treatment often reaches ₹3 lakh.
- Marginal Relative Savings: When expenses run into lakhs, small reductions do not substantially change affordability for middle- and low-income families.
- Delay in Relief Funds: Government relief schemes such as PM or CM relief funds are often slow, uncertain, and time-consuming for rapidly progressing diseases like cancer.
- Emotional and Economic Stress: Families frequently face job loss, asset sales, and debt due to prolonged treatment cycles.
Insurance Coverage Gaps in Cancer Care
- Low Insurance Penetration: Only about 20% of Indians are covered by social health schemes, while 30% have no health cover at all.
- Ayushman Bharat Limitations: Although Ayushman Bharat covers around 50% of the population, many advanced therapies fall outside standard package rates.
- Sub-limits on Advanced Therapies: Immunotherapy and targeted treatments are often capped at ₹2 lakh or 50% of sum insured, despite costs of ₹2–6 lakh per cycle.
- Rapid Exhaustion of Coverage: Insurance amounts like ₹10 lakh may last only 3–4 months for patients on high-cost regimens.
Patent Protection and Drug Pricing Structure
- Monopoly Pricing: Many exempted drugs are under patent protection, with only one global manufacturer, keeping prices high.
- Role of Generics: Prices are expected to fall significantly once patents expire and Indian generic manufacturers enter the market.
- Dosage Dependency: Higher dosage requirements (e.g., 400 mg/day vs 100 mg/day) sharply raise costs, limiting the real benefit of duty exemptions.
- Insurance Advantage: Lower drug prices help insured patients by allowing coverage to stretch longer, improving treatment adherence.
India’s Healthcare Financing Challenge
- High Out-of-Pocket Expenditure: Around 60–70% of healthcare spending in India is borne directly by households.
- Health Spending Levels: India spends about 2.1% of GDP on public health, lower than many comparable economies.
- Catastrophic Health Expenditure: Cancer remains a leading cause of medical impoverishment, pushing families below the poverty line.
- Equity Concerns: Advanced treatments risk becoming accessible only to a small, affluent section of society.
Conclusion
Customs duty exemptions on cancer drugs are a positive but insufficient step. A sustainable solution requires expanding insurance coverage for advanced therapies, faster disbursal of public relief funds, promotion of domestic manufacturing of patented drugs, and higher public investment in health. Without structural reforms, tax cuts alone cannot ensure equitable access to life-saving cancer treatments.
EXPECTED QUESTIONS FOR UPSC CSE
Prelims MCQ
Q. Customs duty exemption on cancer drugs primarily aims to:
(a) Promote exports
(b) Reduce treatment costs of advanced therapies
(c) Encourage private hospitals
(d) Replace insurance schemes
Answer: (b)
Descriptive Question
Q. Critically examine the effectiveness of tax exemptions on cancer drugs in improving healthcare affordability in India. (GS 2&3; 150 Words, 10 Marks)